NCT06168383View on ClinicalTrials.gov

To Evaluate the Efficacy and Safety of HSK31679 in Chinese Patients With Non-Alcoholic Steatohepatitis (NASH) .

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

November 23, 2023

Primary Completion Date

January 31, 2026

Study Completion Date

April 30, 2026

Conditions
Non-Alcoholic Steatohepatitis (NASH)
Interventions
DRUG

HSK31679 80mg

once daily, oral administration of HSK31679 80mg from Day 1 to Week 52.

DRUG

HSK31679 160mg

once daily, oral administration of HSK31679 160mg from Day 1 to Week 52.

DRUG

Placebo

once daily, oral administration of placebo from Day 1 to Week 52.

Trial Locations (1)

Unknown

Beijing Tsinghua Changgung Hospital, Tsinghua University, Beijing

All Listed Sponsors
lead

Haisco Pharmaceutical Group Co., Ltd.

INDUSTRY

NCT06168383 - To Evaluate the Efficacy and Safety of HSK31679 in Chinese Patients With Non-Alcoholic Steatohepatitis (NASH) . | Biotech Hunter | Biotech Hunter